For some time, we at Oncodia have seen cancer diagnostics software used in the clinical practice, which reports false-positive somatic mutations. To demonstrate and try to quantify this, we invented a simple logical test that we call the “Basic Oncodia Test” (B.O.T.). Does your mutation-analysis pipeline pass our B.O.T.?
Advanced cancer diagnostics is based on comparison of the tumor- and normal-tissue sequencing data from the same patient. The aim of the precision tools is to identify the mutations in the tumor, which can be exploited by personalized anti-cancer therapies. What happens if the state-of-the-art tools are provided with identical data input for both the tumor and normal sample? Well, surprisingly many mutations may still be reported. All of them are clearly false-positive, since a trustworthy analysis would report zero mutations when comparing identical datasets.
Oncodia’s VARify passes B.O.T., and filters out additional false-positive mutations for a clinically relevant report. Better mutation profile will guide the choice of a better oncological therapy.
More information about VARify and the B.O.T. is available in the following link:
We are always happy to hear the feedback and comments of our customers, so please do not hesitate to contact us with any questions concerning our products.
